CareDx closes Naveris acquisition, expanding oncology diagnostics

Key Facts

1CareDx announced the successful completion of its acquisition of Naveris after all closing conditions were satisfied.

2The company said the deal had previously been announced in April 2026, and Naveris's lead product is NavDx, a blood-based test for viral-mediated cancers.

As diagnostics companies look for growth beyond their core franchises, CareDx said it has completed its acquisition of Naveris after all closing conditions were satisfied. The company said the deal had previously been announced in April 2026. It added that Naveris’s lead product is NavDx, a blood-based test for viral-mediated cancers.

The closing extends CareDx further into specialty oncology diagnostics alongside its transplant and cell therapy businesses. It is a clear attempt to broaden the company’s diagnostics platform by adding a blood test aimed at a specialized patient set. While the deal was already known, completion removes part of the execution uncertainty around integration and rollout.

Investors will now watch CDNA at $28.50 as of the June 30, 2026 close, after trading between $27.87 and $29.49 during the session. The market will also look for operational updates on how Naveris is folded into the platform, as well as any new company or sector catalysts that could reshape the specialty diagnostics growth story.